Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related NVS
Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right'
How Big Pharma Uses Charity Programs To Cover Drug Price Hikes
Roche/Biogen Drug Gazyva Beats Rituxan In Cancer Trial (Investor's Business Daily)
Related ZIOP
15 Stocks Moving In Thursday's Pre-Market Session
6 Stocks Trending In Short-Selling Circles: Seadrill, Tesla, Weight Watchers And More

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

DateFirmActionFromTo
Apr 2016Morgan StanleyDowngradesEqual-weightUnderperform
Apr 2016Argus ResearchInitiates Coverage onHold
Apr 2016UBSDowngradesBuyNeutral

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (IEX + NVS)

View Comments and Join the Discussion!